Tarsons Products Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, following a Board Meeting on February 06, 2026. The company reported consolidated revenue from operations of ₹97.27 Crores for Q3 FY26, representing a 20.91% increase from ₹80.45 Crores in the previous quarter (QoQ) and a significant 33.72% rise from ₹72.74 Crores in the corresponding quarter of the previous year (YoY). Consolidated profit after tax for the quarter stood at ₹15.82 Crores, reflecting a robust 44.21% growth from ₹10.97 Crores in the previous quarter and a 16.24% increase from ₹13.61 Crores in the same period last year.

Tarsons Products Limited is a leading Indian life sciences company engaged in the design, development, manufacturing, and marketing of a wide range of laboratory plasticware used in research organizations, academic institutes, pharmaceutical companies, and diagnostic labs. In early 2026, the company approved a further equity infusion of EUR 3 Million into its Singapore-based wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., to fund operational expenses and repay existing loans. Additionally, the Board appointed Mr. Vinesh Mohan Kriplani as an Additional Director (Non-Executive Independent) for a five-year term starting February 06, 2026, following the resignation of Mr. Girish Paman Vanvari. The company continues to strengthen its global footprint through its indirect German subsidiaries, Nerbe plus GmbH & Co. KG and Nerbe R&D GmbH.